Imran Ashraf, MD
Gastroenterology · Jefferson City, MONPI 1659683498
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 90.2% of the total across 134 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 20 manufacturers reported payments, led by AbbVie at 50.6% of the total. Reporting peaked in 2023 at $463 and has fallen 56.2% since, to $203 in 2025. That places this record below the midpoint for gastroenterology clinicians in MO, where the typical reported total is $1,415.
Across 134 payments — averaging $13.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$934
- Johnson & Johnson$235
- Aimmune Therapeutics, Inc.$145
- Takeda Pharmaceuticals U.S.A., Inc.$74
- Nestle Healthcare Nutrition Inc.$64
- Bristol Myers Squibb$55
- plus $341 from 14 others
Across 67 payments — averaging $1707.51 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bausch Health US, LLC$114K
What the payments were for
- Food & beverage$1,66590%
- Education$18110%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 91 | $934 |
| Johnson & Johnson(2 entities) | 5 | $235 |
| Aimmune Therapeutics, Inc. | 8 | $145 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $74 |
| Nestle Healthcare Nutrition Inc. | 4 | $64 |
| Bristol Myers Squibb | 3 | $55 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $51 |
| Daiichi Sankyo Inc. | 2 | $49 |
| Pfizer | 2 | $35 |
| Integra Lifesciences Corporation | 1 | $35 |
| Pharmacosmos Therapeutics Inc. | 1 | $22 |
| Alfasigma USA, Inc. | 1 | $22 |
| Ferring Pharmaceuticals Inc. | 1 | $22 |
| Organon | 1 | $20 |
| Amgen | 1 | $19 |
| UCB, Inc. | 1 | $15 |
| Ipsen Biopharmaceuticals, Inc | 1 | $15 |
| Phathom Pharmaceuticals, Inc. | 1 | $13 |
| Merck | 1 | $12 |
| Ironwood Pharmaceuticals, Inc | 1 | $11 |
How this compares
$1,846 in reported general payments places this provider in the 50th percentile of 374 gastroenterology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 36 | $1,019,455 |
| Humira(Cf) PenAdalimumab | 14 | $101,247 |
| EntyvioVedolizumab | 11 | $99,371 |
| ZenpepLipase/Protease/Amylase | 13 | $84,889 |
| LinzessLinaclotide | 14 | $11,686 |
| Mesalamine | 39 | $10,507 |
| Mesalamine ErMesalamine | 37 | $9,359 |
| Balsalazide Disodium | 39 | $5,178 |
| Omeprazole | 222 | $3,732 |
| Pantoprazole Sodium | 233 | $3,428 |
| Esomeprazole Magnesium | 37 | $3,218 |
| Dexlansoprazole DrDexlansoprazole | 12 | $3,079 |
| Budesonide DrBudesonide | 11 | $3,060 |
| Dicyclomine Hcl | 82 | $1,879 |
| Famotidine | 87 | $1,547 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $235 | $1,019,45536 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Entyvio | $74 | $99,37111 claims |
| Aimmune Therapeutics, Inc.Zenpep | $145 | $84,88913 claims |
| AbbVieLinzess | $934 | $11,68614 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 374 gastroenterology providers in Missouri.
Other gastroenterology in Jefferson City
- Gregory SayukSaint Louis$1.1M
- Katie SchroederSaint Louis$730K
- David AlpersSaint Louis$616K
- Kamran QureshiLake St Louis$279K
- Laith Al MomaniKansas City$249K
- Ahmed SaeedKansas City$246K
- Parakkal DeepakSaint Louis$205K
- Bradley AndersonColumbia$194K
- Mauricio Lisker MelmanSaint Louis$179K
- Matthew CiorbaSaint Louis$156K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.